CA2079450A1 - Interaction entre des liposomes bioadhesifs et leurs sites - Google Patents

Interaction entre des liposomes bioadhesifs et leurs sites

Info

Publication number: CA2079450A1
Authority: CA; Canada
Prior art keywords: component; administration; liposome; recognizing substance; target site
Prior art date: 1991-02-14
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002079450A

Other languages

English (en)

Inventor

Rimona Margalit

Theodore Roseman

Ray W. Wood

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Baxter International Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-02-14

Filing date

1991-10-30

Publication date

1992-08-15

1991-10-30 Application filed by Individual filed Critical Individual

1992-08-15 Publication of CA2079450A1 publication Critical patent/CA2079450A1/fr

Status Abandoned legal-status Critical Current

Links

239000002502 liposome Substances 0.000 title claims abstract description 37
239000000227 bioadhesive Substances 0.000 title abstract description 6
230000003993 interaction Effects 0.000 title 1
239000000126 substance Substances 0.000 claims abstract description 48
229920001436 collagen Polymers 0.000 claims abstract description 19
102000008186 Collagen Human genes 0.000 claims abstract description 18
108010035532 Collagen Proteins 0.000 claims abstract description 18
230000001413 cellular effect Effects 0.000 claims abstract description 15
102000009024 Epidermal Growth Factor Human genes 0.000 claims abstract description 14
230000014759 maintenance of location Effects 0.000 claims abstract 10
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract 4
101800003838 Epidermal growth factor Proteins 0.000 claims abstract 4
108010010803 Gelatin Proteins 0.000 claims abstract 4
229960005188 collagen Drugs 0.000 claims abstract 4
229940116977 epidermal growth factor Drugs 0.000 claims abstract 4
229920000159 gelatin Polymers 0.000 claims abstract 4
239000008273 gelatin Substances 0.000 claims abstract 4
235000019322 gelatine Nutrition 0.000 claims abstract 4
235000011852 gelatine desserts Nutrition 0.000 claims abstract 4
229920002674 hyaluronan Polymers 0.000 claims abstract 4
229960003160 hyaluronic acid Drugs 0.000 claims abstract 4
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims abstract 4
238000000034 method Methods 0.000 claims description 29
230000007246 mechanism Effects 0.000 claims 9
239000003431 cross linking reagent Substances 0.000 claims 4
108010037362 Extracellular Matrix Proteins Proteins 0.000 claims 3
102000010834 Extracellular Matrix Proteins Human genes 0.000 claims 3
JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims 3
210000002744 extracellular matrix Anatomy 0.000 claims 3
150000008104 phosphatidylethanolamines Chemical class 0.000 claims 3
239000002691 unilamellar liposome Substances 0.000 claims 3
230000000699 topical effect Effects 0.000 claims 2
229940079593 drug Drugs 0.000 abstract description 41
239000003814 drug Substances 0.000 abstract description 41
229940014259 gelatin Drugs 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 40
102000005962 receptors Human genes 0.000 description 14
108020003175 receptors Proteins 0.000 description 14
101710098940 Pro-epidermal growth factor Proteins 0.000 description 10
230000000694 effects Effects 0.000 description 3
102000001301 EGF receptor Human genes 0.000 description 2
108060006698 EGF receptor Proteins 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
ODPOAESBSUKMHD-UHFFFAOYSA-L 6,7-dihydrodipyrido[1,2-b:1',2'-e]pyrazine-5,8-diium;dibromide Chemical compound [Br-].[Br-].C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 ODPOAESBSUKMHD-UHFFFAOYSA-L 0.000 description 1
239000005630 Diquat Substances 0.000 description 1
208000010412 Glaucoma Diseases 0.000 description 1
101000851196 Mus musculus Pro-epidermal growth factor Proteins 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
241001163743 Perlodes Species 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
238000003556 assay Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
239000003292 glue Substances 0.000 description 1
239000003446 ligand Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
239000003550 marker Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
239000000203 mixture Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
210000003370 receptor cell Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Dispersion Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Seats For Vehicles (AREA)
Electric Cable Arrangement Between Relatively Moving Parts (AREA)

CA002079450A 1991-02-14 1991-10-30 Interaction entre des liposomes bioadhesifs et leurs sites Abandoned CA2079450A1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US65501391A	1991-02-14	1991-02-14
US7/655,013		1991-02-14

Publications (1)

Publication Number	Publication Date
CA2079450A1 true CA2079450A1 (fr)	1992-08-15

Family

ID=24627144

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002079450A Abandoned CA2079450A1 (fr)	1991-02-14	1991-10-30	Interaction entre des liposomes bioadhesifs et leurs sites

Country Status (5)

Country	Link
EP (1)	EP0525154A1 (fr)
JP (1)	JPH05506040A (fr)
AU (1)	AU656173B2 (fr)
CA (1)	CA2079450A1 (fr)
WO (1)	WO1992014446A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9208339D0 (en) *	1992-04-15	1992-06-03	Unilever Plc	Treatment composition
AU6268894A (en) *	1993-02-22	1994-09-14	Alza Corporation	Compositions for oral delivery of active agents
US6096863A (en) *	1996-08-23	2000-08-01	Regents Of The University Of Minnesota	Self-assembling amphiphiles for construction of peptide secondary structures
US6890901B2 (en)	1996-09-27	2005-05-10	Jagotec Ag	Hyaluronic drug delivery system
US20030180348A1 (en) *	2002-03-22	2003-09-25	Levinson R. Saul	Transcellular drug delivery system
JP5695308B2 (ja) *	2009-10-02	2015-04-01	株式会社フェース	コラーゲン修飾リポソームからなる化粧料基剤およびそれを含有する皮膚化粧料
EP2522366B1 (fr) *	2010-01-08	2018-10-31	FUJIFILM Corporation	Agent de ciblage pour site tumoral
JP5756602B2 (ja) *	2010-04-16	2015-07-29	株式会社フェース	ゼラチンおよび／またはエラスチン構成ポリペプチドで修飾されたリポソームからなる化粧料基剤およびそれを含有する皮膚化粧料

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5000960A (en) *	1987-03-13	1991-03-19	Micro-Pak, Inc.	Protein coupling to lipid vesicles
GB8713747D0 (en) *	1987-06-12	1987-07-15	Unilever Plc	Skin treatment composition
US5064655A (en) *	1989-02-24	1991-11-12	Liposome Technology, Inc.	Liposome gel composition and method
AU652778B2 (en) *	1990-10-15	1994-09-08	Quest International B.V.	Treatment composition
ATE127685T1 (de) *	1991-02-14	1995-09-15	Baxter Int	Verzögerte arzneistoffabgabe durch topische anwendung bioadhäsiver liposomen.

1991
- 1991-10-30 JP JP92505165A patent/JPH05506040A/ja active Pending
- 1991-10-30 CA CA002079450A patent/CA2079450A1/fr not_active Abandoned
- 1991-10-30 EP EP19920904871 patent/EP0525154A1/fr not_active Withdrawn
- 1991-10-30 AU AU12592/92A patent/AU656173B2/en not_active Ceased
- 1991-10-30 WO PCT/US1991/008112 patent/WO1992014446A1/fr not_active Application Discontinuation

Also Published As

Publication number	Publication date
WO1992014446A1 (fr)	1992-09-03
EP0525154A1 (fr)	1993-02-03
AU656173B2 (en)	1995-01-27
JPH05506040A (ja)	1993-09-02
AU1259292A (en)	1992-09-15

Publication	Publication Date	Title
Schaeffer et al.	1982	Liposomes in topical drug delivery.
AU718460B2 (en)	2000-04-13	Ionophore-mediated liposome loading of weakly basic drug
WO1990009782A1 (fr)	1990-09-07	Composition liposomique sous forme de gel et son procede de preparation
CA2120197A1 (fr)	1994-10-03	Dispersions aqueuses stables renfermant des liposomes
WO1996010394A1 (fr)	1996-04-11	Procede de liaison de substances de reconnaissance a des liposomes
CA2079450A1 (fr)	1992-08-15	Interaction entre des liposomes bioadhesifs et leurs sites
US20100129430A1 (en)	2010-05-27	Liposome drug carriers with ph-sensitivity
WO1999042085A1 (fr)	1999-08-26	Dispersion liposomale d'erythropoietine
CA2079685A1 (fr)	1992-08-03	Vesicules a membrane synthetique contenant des peptides de fusion fonctionnellement actives en tant que systeme d'administration de medicaments
TWI230616B (en)	2005-04-11	Liposome for incorporating large amounts of hydrophobic substances
CN102038640B (zh)	2013-11-13	一种含有胆固醇的peg修饰物的脂质体药物及其制备方法
CN102188363B (zh)	2013-02-27	含有多奈哌齐化合物的透皮给药系统及制剂和制备方法
AU2008295666B2 (en)	2013-05-16	Improved liposomes and uses thereof
CA2079447C (fr)	2004-02-10	Administration continue de medicaments par application topique de liposomes bioadhesifs
EP2531222B1 (fr)	2014-04-02	Liposomes contenant de la prostaglandine e1 (pge1), formulations les contenant et utilisation associée
US20240108579A1 (en)	2024-04-04	Utidelone liposome composition, and preparation method therefor and use thereof
KR20040051958A (ko)	2004-06-19	폴리에틸렌글리콜 결합 스핑고지질 유도체
BRPI1015542B1 (pt)	2022-05-10	Um método para tratar bexigas hiperativas e um dispositivo para armazenamento e administração de composições tópicas de oxibutinina
AU2016206387B2 (en)	2017-05-25	Ready-to-use formulation for vincristine sulfate liposome injection
CN103705439B (zh)	2017-11-28	脂质凝胶药物制剂及其制备方法和用途
EP3445334B1 (fr)	2024-10-09	Nanoliposomes pour administration prolongée de tacrolimus pour le traitement de maladies oculaires du segment antérieur
WO2008153570A1 (fr)	2008-12-18	Supports de médicaments liposomiques dotés d'une sensibilité au ph
FARSHI et al.	0	liposomal dexamethasone sodium phosphate
CN114933569A (zh)	2022-08-23	鞘脂类化合物、含有鞘脂类化合物的脂质体和应用
JPH02273538A (ja)	1990-11-08	リポソームの保存方法

Legal Events

Date	Code	Title	Description
1998-10-16	EEER	Examination request
2002-10-30	FZDE	Dead